Company intelligence / Profile preview

ErVimmune

Lyon, Auvergne-Rhône-Alpes, Franceervimmune.com ↗

Ownership: Private
Development stage: Phase 1

Overview

As of early 2026, ErVimmune is transitioning into its first-in-human clinical phase following a €17 million Series A funding round. The lead program, ErVac01, is an off-the-shelf therapeutic cancer vaccine designed to target human endogenous retrovirus (HERV) antigens in patients with triple-negative breast cancer and ovarian cancer. The company aims to establish safety and immunogenicity in these initial clinical trials.

Therapeutic areas: OncologyHematology
Modalities: VaccineCell therapyT cell receptor engineered T cell therapyTherapeutic vaccineTCR-T cell therapyRecombinant vector vaccine
Industry: Biotech

Drug pipeline

4 assets

ErVac01

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Servier

Beyond the preview

Go deeper on ErVimmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ErVimmune.

Explore the full profile